Market research
IGX.V IntelGenx Technologies Corp
V CAD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 90M
- P/E ratio
- Not available
- Analyst target
- 0.99
- Dividend yield
- 0.0%
- Beta
- 2.56
Profile
Instrument facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 90M
- P/E ratio
- Not available
- Analyst target
- 0.99
- Dividend yield
- 0.0%
- Beta
- 2.56
About
About IntelGenx Technologies Corp
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Research context
IntelGenx Technologies Corp appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the IGX.V discussion.
5 years, 6 months ago
IntelGenx Technologies Corp is currently in a long term uptrend where the price is trading 38.7% above its 200 day moving average.
From a valuation standpoint, the stock is 96.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 34.1.
IntelGenx Technologies Corp's total revenue rose by 1061.8% to $790K since the same quarter in the previous year.
Its net income has increased by 52.0% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 76.0% to $-533K since the same quarter in the previous year.
Based on the above factors, IntelGenx Technologies Corp gets an overall score of 5/5.